Aiforia complies with applicable HIPAA regulations, enabling it to provide solutions to a broader range of customers in the US
Aiforia Technologies Plc, Press Release, 18 September 2023 at 09:00 a.m. EEST
Written by Aiforia
Aiforia and Orion collaborate to develop AI solutions for image analytics in drug research
Aiforia Technologies Plc, Press Release, 05 July 2023 at 12:00 a.m. EEST
Written by Aiforia
Aiforia signs a major deal with an Italian Regional Health Authority
Aiforia Technologies Plc Inside information 29 June 2023 at 10:30 a.m. EEST
Written by Aiforia
April 27, 2023
Aiforia has received a funding decision from Business Finland to accelerate the development of AI-assisted software solutions for clinical pathology and drug development
Aiforia Technologies Plc, Company release, 27 April 2023 at 12:00 a.m. EEST. Aiforia has received a funding decision from Business Finland to accelerate the development of AI-assisted software solutions for clinical pathology and drug development.
Written by Aiforia
April 4, 2023
First NHS Trust has signed a contract to adopt Aiforia PD-L1 AI model for lung cancer in clinical diagnostics
Aiforia Technologies Plc, Press Release, 04 April 2023 at 12:00 a.m. EEST. The first NHS Trust of the PathLAKE Plus consortium has signed an individual contract to adopt Aiforia PD-L1 AI model for lung cancer in clinical diagnostics. The duration of the contract is three years, with a possible three-year extension.
Written by Aiforia
March 10, 2023
Aiforia Technologies Plc appoints Vice President of Marketing
Aiforia Technologies Plc appoints a new Vice President of Marketing who brings international experience in various commercial positions both in the field of tissue diagnostics and targeted therapies for cancer.
Written by Aiforia